Quadruple-Action RoclatanTM Phase 2b Highlights RoclatanTM achieved its main efficacy endpoint of statistically significant superiority over each of its elements on time 29. The Phase 2b 28-day medical trial included 297 patients. The baseline intraocular pressures examined in the study ranged from 22 to 36 millimeters of mercury . RoclatanTM lowered mean diurnal IOP on day 29 from 25.1 mmHg at baseline to 16.5 mmHg, a 34 % decrease in IOP. RoclatanTM indicate diurnal IOP reduction on day time 29 was approximately 2 mmHg higher than latanoprost.You will see the entire Kaiser Daily Health Policy Survey, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, discussions and debates. The Daily Health Policy Report is released for Kaisernetwork.org, a free of charge services of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Panel Kaiser and Company Family members Foundation. All rights reserved.. ACT signs agreement to choose novel clinical applicants for just two cancer metabolic programs Advanced Cancer Therapeutics , a held company dedicated to bringing new anti-cancer therapies to advertise privately, today announced that this has signed an exclusive contract to leverage the translational research knowledge of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville’s James Graham Dark brown Cancer Center , to identify new clinical candidates for the prevention and treatment of cancers against two key malignancy metabolic targets.